Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication

Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.

Investors reacted quickly and negatively when Aptinyx Inc. reported that lead candidate NYX-2925 missed the primary endpoint in a Phase II diabetic peripheral neuropathy (DPN) study Jan. 16, but CEO Norbert Riedel maintained the data for the NMDA receptor modulator in both DPN and fibromyalgia will help build a case for a labeling claim encompassing the spectrum of chronic pain.

The Chicago-area firm saw its stock lose nearly two-thirds of its value, closing down 66.5% on Jan. 16 at $5.98...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category